Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited , today announced the completion of patient enrollment in a phase III clinical trial of ADCETRIS for post-transplant Hodgkin lymphoma patients.
